Socket Mobile Dips Below $1 Mark Again as Nasdaq Deadline Nears

Socket Mobile Dips Below $1 Mark Again as Nasdaq Deadline Nears

June 3, 2026

NEW YORK, June 3, 2026, 16:05 EDT

Socket Mobile traded under $1 again Wednesday. The data-capture tech company is still facing a Nasdaq listing issue tied to the price. Last trade was $0.9039, a gain of around 0.4%. Intraday range was $0.90 to $0.98. Volume came in at 229,471 shares, putting the company’s market cap near $7.4 million.

Nasdaq notified Socket Mobile on May 19 that its shares closed under $1 for 30 business days in a row. Stocks on the exchange have to keep a bid price of at least $1 to hold on to their listing. Socket needs to get the price back above $1 for at least 10 business days in a row by Nov. 16, 2026, or it risks starting the delisting process. If that happens, trading the stock can get tougher and raising money in the public market can take a hit.

Socket’s stock is trading under a dollar, near a key financing level. In March, the company closed a $500,000 secured subordinated convertible note. The debt is backed by company assets, but it stands behind senior lenders, and it is convertible to stock. The note pays 10% annual interest and can convert at $0.90 a share.

Socket’s first-quarter results didn’t ease investor nerves. The Fremont, California company posted revenue of $3.7 million, off 7% from both a year ago and from Q4 2025. Operating loss improved to $0.8 million from $0.9 million. Gross margin was 51.3%, up from 50.4%. CEO Kevin Mills said results “fell short of expectations” and blamed “customer caution and delayed spending.”

Socket Mobile, Inc. makes barcode scanners, contactless readers and software for mobile apps. Products are used for point-of-sale, field service, tracking assets, manufacturing, logistics, event management, medical, and education. The investor page lists 52 employees.

Socket’s product updates lately have focused on finding a place for its hardware in larger platforms, not moving away from small-company economics. On May 4, the company rolled out SM Link, a $20 USB adapter aimed at connecting its Bluetooth barcode and NFC readers to Macs. NFC, or near-field communication, is used for things like passes, badges, and stored credentials. “Customers have been asking for Mac support,” Chief Business Officer Dave Holmes said. Socket Mobile, Inc.

Socket said in April that Shopify version 11.0.0 works with its SocketScan S721 and S741 scanners, so Shopify merchants can use those devices at checkout, for inventory, or for ID checks. Holmes called expanding to Shopify “an important step” for customers and partners. Socket Mobile, Inc.

Microcaps with low trading volumes face a tough time in this market. Shares of Zebra Technologies, a bigger barcode and enterprise mobile device player, dropped 2.3% late Wednesday. Honeywell, active in automation gear that touches some of the same areas, lost 5.1%. For Socket, trading at a much smaller scale, listing risk, thin liquidity and financing terms may end up counting more than what happens with larger peers.

Small-cap stocks also traded lower, with the iShares Russell 2000 ETF falling 1.4%. The fund, which tracks U.S. small-caps, is a go-to gauge for those looking to distinguish between single-name trouble and broader small-cap weakness.

Socket is selling its products, but the focus is on the stock price. Investors are looking at the bid, where even pennies count as the exchange looks for $1.

Stock Market Today

  • Telix Pharmaceuticals Shares Lead ASX 200 Gains Amid Clinical Trial Updates
    June 9, 2026, 8:39 PM EDT. Telix Pharmaceuticals shares surged 0.6% to A$13.39, topping the ASX 200 despite the broader market's 0.24% decline. The radiopharmaceutical firm, valued at about A$4.54 billion, is buoyed by positive data from its Phase 3 ProstACT Global clinical trial in metastatic prostate cancer and a new U.S. collaboration with United Imaging Healthcare North America. Telix reported a 24% revenue increase to US$230 million in Q1 and reaffirmed its 2026 revenue outlook between US$950 million and US$970 million. Meanwhile, market optimism contrasts with declines in competitors like Clarity Pharmaceuticals, reflecting investor focus on Telix's growth prospects in precision medicine and cancer imaging.